Literature DB >> 28486739

[Castleman's Disease - A Case Series of a Rare Lymphoproliferative Disease].

Ricarda Riepl1, Thomas Karl Hoffmann1, Jens Greve1.   

Abstract

Castleman's disease is a very rare and potentially severe lymphoproliferative disorder. First sign may be cervical lymphadenitis, requiring sufficient support in diagnosis and therapy by an ENT specialist. Based on a case series the current manuscript gives an overview of the symptoms, the course of disease and the therapy options. Patients with the first diagnosis of a Castleman's disease at the ENT clinic of Ulm University during the years 2011-2015 were included. The duration of symptoms, the applied diagnostic and therapeutic algorithms were evaluated. The duration of the rather weak symptoms was inhomogenous and lasted from 14 days to 14 years. After diagnostic exstirpation a hyaline-vascular type of Castelman's disease was confirmed in all cases. One of the 5 cases proved a multicentric type with an additional axillary manifestation, the others were monocentric. In all patients the diagnostic exstirpation was sufficient for therapy without need for adjuvant medication. At the time of publication all patients are in remission for at least 18 resp. 61 months. The ENT specialist encounters Castleman's disease mostly as a long-lasting swelling of cervical lymph nodes refractory to therapy and without severe concomittant symptoms. Due to potentially unfavorable outcomes a timely diagnostic lymph node exstirpation under general anesthesia is indicated. In most cases this surgical intervention represents the sufficient therapy. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2017        PMID: 28486739     DOI: 10.1055/s-0043-102058

Source DB:  PubMed          Journal:  Laryngorhinootologie        ISSN: 0935-8943            Impact factor:   1.057


  2 in total

Review 1.  Castleman's Disease: A Rare Mass in the Pararenal Retroperitoneum that Mimics Other Tumors.

Authors:  Yi Xie; Yi Zhao; Zhi-Gang Ji; Han-Zhong Li; Guang-Hua Liu; Quan-Zhong Mao
Journal:  Chin Med J (Engl)       Date:  2017-09-05       Impact factor: 2.628

2.  Siltuximab-Related Favorable Clinical Outcome for a Patient Suffering from Idiopathic Multicentric Castleman Disease.

Authors:  Stamatios Chrysochoou; Andreas Kreft; Eberhard Schneider
Journal:  Case Rep Hematol       Date:  2022-03-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.